|
Administration
May be taken with or without food.
|
|
Special Precautions
Patient w/ CV disease, epilepsy, history of convulsions or those w/ predisposing factors for epilepsy. Conditions that may increase urinary pH (e.g. drastic dietary changes). Moderate to severe renal and severe hepatic impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor cognitive function; periodic ophth examination.
|
|
Adverse Reactions
Headache, dizziness, constipation, HTN, somnolence, anxiety, confusion, hallucinations, fatigue, abnormal gait, hypertonia, vomiting, fungal infections, cystitis, thromboembolism, increased libido, psychotic reactions, pancreatitis; agranulocytosis, leucopenia (including neutropenia), thrombocytopenia, pancytopenia, thrombotic thrombocytopenic purpura, CHF, hepatitis, suicidal ideation, acute renal failure (including increased creatinine and renal impairment), Stevens-Johnson syndrome.
|
|
Drug Interactions
Increased risk of adverse effects w/ amantadine, ketamine or dextromethorphan. May decrease the effects of barbiturates and neuroleptics. May increase the effects of L-dopa, dopaminergic agonists and anticholinergics. May alter the effect of antispasmodics (e.g. dantrolene, baclofen). Decreased clearance w/ carbonic anhydrase inhibitors and Na bicarbonate. May potentially increase plasma levels of cimetidine, procainamide, ranitidine, quinidine, quinine, nicotine. May decrease serum level of hydrochlorothiazide.
|
|
CIMS Class
|
|
ATC Classification
N06DX01 - memantine ; Belongs to the class of other anti-dementia drugs.
|
Sign Out
